


To Whom It May Concern,

February 28, 2023

BioSpectra Inc. has hosted the following Customer Audits and US FDA Inspection between the years 2020 and 2023 including the proposed 2023 schedule. The completed audits were hosted at the manufacturing sites Rockdale Lane and/or Majestic Way in Pennsylvania either onsite or virtually with the onsite US FDA inspection focused on Majestic Way.

Table 1. Customer and Regulatory Agency Audits 2020-Present

Month/Year	Name
January 2020	Pfizer
February 2020	Merck
March 2020	Dechra Veterinary Products
June 2020	JNJ Janssen
August 2020	Avantor Performance Chemicals
October 2020	Eli Lilly and Company
November 2020	Generic Pharma International
December 2020	Sanofi
February 2021	AstraZeneca
March 2021	Berkshire Sterile Manufacturing
March 2021	Serum Institute of India
April 2021	Moderna
April 2021	Emergent BioSolutions
April/May 2021	US FDA
June 2021	UCB
June 2021	Translate Bio
July 2021	Regeneron
July 2021	BSP Pharmaceuticals SPA
July 2021	scPharmaceuticals
July 2021	Biocon Biologics Limited
August 2021	JNJ
August 2021	Fujifilm
September 2021	B.Braun
October 2021	Gilead Sciences
January 2022	ThermoFisher Scientific
April 2022	Bristol Myers Squibb
May 2022	Ultragenyx Pharmaceutical
June 2022	EMD Merck Millipore
June 2022	Gilead Sciences
October 2022	Lonza Biologics
October 2022	Avantor Performance Chemicals
November 2022	KSE Scientific
February 2023	Hawkins



Month/Year	Name
February 2023	Biogen
February 2023	Viatris
March 2023	Bausch + Lomb
March 2023	Moderna
March 2023	Bionovis S.A.
March 2023	Resilience US
March 2023	AstraZeneca
April 2023	Avantor
April 2023	Gilead Sciences
May 2023	Sanofi

Sincerely,

BioSpectra's Compliance Department

BioSpectra Inc.
100 Majestic Way
Bangor, PA 18013